Cresilon
Brooklyn, US · Delaware corporation · 4 known investors
Find your way into Cresilon
545 people in our graph share verified history with the Cresilon team — schools, employers, funds. One of them is your warm intro.
Lyle McCullochunlockedknows Scott Levine · together at Coopers & Lybrand (overlapped)
×7knows the team · via Coopers & Lybrand
×4knows the team · via University at Buffalo
Cresilon develops plant-based flowable hemostatic gel technology that controls bleeding within seconds without manual pressure, with products for veterinary care (VETIGEL) and human trauma (TRAUMAGEL). Its customers include EMS agencies, trauma hospitals, military, law enforcement, and veterinary practices.
Founders & leadership
IM
Isaac MillerinEVP & Co-Founder
JL
SL
Scott LevineinChief Financial OfficerHe brings experience as a CFO at private and public companies, with expertise in financial planning and analysis in technology-enabled services, and a track record of managing financing rounds and exits.
Investors · 4
Catalio Capital Management, LPNew York
Dorm RoomBrooklyn · $90K – $250K
Innovating CapitalNew York · $10K – $3M
Also in the syndicate · 1
Paulson Investment Companylead
Funding
SEC filings, press & company announcements$157.9M disclosed across 8 of 10 rounds · 2017–2026
- Undisclosed amountSeries A-4Oct 2022
Paulson Investment Company (lead)
Source ↗
▶$29MraisedJun 2026 · 217 investors · BiotechnologyRule 506(c)
▶$29MraisedJun 2026 · 217 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Joseph LandolinaExecutive Officer, Director
- Isaac MillerDirector
- Scott LevineExecutive Officer
- Offering amount
- $29M
- Amount sold
- $29M
- Minimum investment
- $10K
- Sales commissions
- $3.4M
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$6.7MraisedDec 2025 · 55 investors · BiotechnologyRule 506(c)
▶$6.7MraisedDec 2025 · 55 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Scott LevineExecutive Officer
- Isaac MillerExecutive Officer, Director
- Joseph LandolinaExecutive Officer, Director
- Offering amount
- $6.7M
- Amount sold
- $6.7M
- Minimum investment
- $25K
- Sales commissions
- $868.8K
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$17.2MraisedSep 2025 · 95 investors · BiotechnologyRule 506(b)
▶$17.2MraisedSep 2025 · 95 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac MillerDirector
- Joseph LandolinaExecutive Officer, Director
- Scott LevineExecutive Officer
- Offering amount
- $34.8M
- Amount sold
- $17.2M
- Minimum investment
- $1.8K
- Sales commissions
- $2.2M
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedJan 2025 · 237 investors · BiotechnologyRule 506(c)
▶$25MraisedJan 2025 · 237 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Joseph LandolinaExecutive Officer, Director
- Isaac MillerExecutive Officer, Director
- Scott LevineExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- Minimum investment
- $5K
- Sales commissions
- $3.1M
- Proceeds to insiders
- $300K
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$17.2MraisedOct 2024 · 309 investors · BiotechnologyRule 506(b)
▶$17.2MraisedOct 2024 · 309 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac MillerDirector
- Scott LevineExecutive Officer
- Joseph LandolinaExecutive Officer, Director
- Offering amount
- $38M
- Amount sold
- $17.2M
- Minimum investment
- $2.3K
- Sales commissions
- $2.2M
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedOct 2022 · 308 investors · BiotechnologyRule 506(c)
▶$25MraisedOct 2022 · 308 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Joseph LandolinaExecutive Officer, Director
- Isaac MillerDirector
- Offering amount
- $25M
- Amount sold
- $25M
- Minimum investment
- $100K
- Sales commissions
- $3.2M
- Proceeds to insiders
- $200K
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$24.5MraisedFeb 2021 · 170 investors · BiotechnologyRule 506(b)
▶$24.5MraisedFeb 2021 · 170 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph LandolinaExecutive Officer, Director
- Isaac MillerExecutive Officer, Director
- Offering amount
- $45.3M
- Amount sold
- $24.5M
- Minimum investment
- $25K
- Sales commissions
- $2.8M
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.3MraisedJan 2018 · 55 investors · BiotechnologyRule 506(b)
▶$13.3MraisedJan 2018 · 55 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac MillerExecutive Officer, Director
- Joseph LandolinaExecutive Officer, Director
- Offering amount
- $19.3M
- Amount sold
- $13.3M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Amogy22 shared keywordsAmogy develops patented ammonia cracking technology that converts ammonia into electric power for hydrogen fuel cells and engines, targeting decarbonization of heavy industries including transportation and maritime. The company offers modular ammonia-to-power systems and high-efficiency catalysts as alternatives to diesel and hydrogen fuel solutions.
Walgreens18 shared keywordsWalgreens operates a pharmacy and retail health and wellness business, offering prescription services, over-the-counter medications, health products, and photo services to consumers.
Bioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Cresilon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Cresilon do?
- Cresilon develops plant-based flowable hemostatic gel technology that controls bleeding within seconds without manual pressure, with products for veterinary care (VETIGEL) and human trauma (TRAUMAGEL). Its customers include EMS agencies, trauma hospitals, military, law enforcement, and veterinary practices.
- Who founded Cresilon?
- Cresilon was founded by Isaac Miller, Joe Landolina.
- Who are Cresilon's investors?
- Cresilon's investors include Catalio Capital Management, LP, Dorm Room, Innovating Capital.
- How much funding has Cresilon raised?
- Cresilon has disclosed $157.9M raised across 8 of its 10 known rounds.
- Where is Cresilon headquartered?
- Cresilon is headquartered in Brooklyn, US.